Cancer clinical trials in the region Bourgogne-Franche-Comté

218 currently recruiting clinical trials
Region Bourgogne-Franche-Comté
Phase 2 Sarcoma and GIST #NCT05182164 #2023-509496-16-00
Required histologic types
Bone sarcoma
Required histologic sub types
Ewing tumor
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
6 recruiting sites
Institut Bergonié, Merck Sharp & Dohme LLC
Phase 2 Skin cancer #NCT06172478 #2023-507641-29-00
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma Lentigo maligna melanoma Superficial spreading melanoma Acral lentiginous melanoma Achromic melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer #NCT05800275
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
11 recruiting sites
UNICANCER
Phase 2 Brain tumors / Central nervous system tumors #NCT02394626
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery Radiotherapy
8 recruiting sites
Insel Gruppe AG, University Hospital Bern
Phase 2 Lymphoma #NCT06271057 #2023-506705-20-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Indolent transformed lymphoma
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07059845 #2025-521606-18-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III Stage IV
Required number of previous lines of therapy for current stage of disease
None 1
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07059845 #2025-521606-18-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III Stage IV
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07059845 #2025-521606-18-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III Stage IV
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2 Thyroid and adrenal gland cancer #NCT03732495
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma Poorly differentiated carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Radioactive iodine
Required radioactive iodine status
Resistant to radioactive iodine
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
14 recruiting sites
Centre Léon Bérard
Phase 2 Acute leukemia #NCT07007052 #2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
9 recruiting sites
French Innovative Leukemia Organisation (FILO)